Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 9 SODIUM CHLORIDE.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs MIDAZOLAM IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance, leading to neuronal hyperpolarization and central nervous system depression.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Initial: 0.5-2 mg IV over 2-3 min; titrate by 0.5-1 mg increments q2-3min as needed; usual total 2.5-5 mg. Continuous infusion: 0.02-0.1 mg/kg/hr IV (1-7 mg/hr). Intranasal: 0.2-0.3 mg/kg (max 15 mg).
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
2-6 hours (prolonged in elderly, obesity, hepatic impairment, or critical illness; up to 12 hours in ICU patients)
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: ~80% as metabolites (primarily 1-hydroxymidazolam glucuronide), <1% unchanged; biliary/fecal: ~2-10%
Category C
Category A/B
Electrolyte
Electrolyte